Although further investigations with regard to haemodynamic regulation and cell death pathways are warranted to fully understand the mechanisms of these therapeutic effects, the current study strongly suggests that LOX and LOXL2 are promising therapeutic targets for CsA-induced nephropathy in transplant patients. This evidence concerns the gene LOX and kidney disorder.